Found: 87
Select item for more details and to access through your institution.
Infectious and immunological sequelae of daratumumab in multiple myeloma.
- Published in:
- Angewandte Chemie, 2019, v. 131, n. 15, p. 187, doi. 10.1111/bjh.15433
- By:
- Publication type:
- Article
Eruptive cherry hemangiomatosis associated with multicentric Castleman disease: a case report and diagnostic clue.
- Published in:
- 2013
- By:
- Publication type:
- journal article
Eruptive Cherry Hemangiomatosis Associated With Multicentric Castleman Disease.
- Published in:
- JAMA Dermatology, 2013, v. 149, n. 2, p. 204, doi. 10.1001/jamadermatol.2013.1552
- By:
- Publication type:
- Article
Teclistamab in relapsed refractory multiple myeloma: multi-institutional real-world study.
- Published in:
- Blood Cancer Journal, 2024, v. 14, n. 1, p. 1, doi. 10.1038/s41408-024-01003-z
- By:
- Publication type:
- Article
Prognostic value of ferritin in ASCT MM patients: integration with GEP models and ISS series systems.
- Published in:
- Blood Cancer Journal, 2024, v. 14, n. 1, p. 1, doi. 10.1038/s41408-024-00998-9
- By:
- Publication type:
- Article
The spatio-temporal evolution of multiple myeloma from baseline to relapse-refractory states.
- Published in:
- Nature Communications, 2022, v. 13, n. 1, p. 1, doi. 10.1038/s41467-022-32145-y
- By:
- Publication type:
- Article
The functional epigenetic landscape of aberrant gene expression in molecular subgroups of newly diagnosed multiple myeloma.
- Published in:
- Journal of Hematology & Oncology, 2020, v. 13, n. 1, p. 1, doi. 10.1186/s13045-020-00933-y
- By:
- Publication type:
- Article
Gamma-Tocotrienol Modulates Total-Body Irradiation-Induced Hematopoietic Injury in a Nonhuman Primate Model.
- Published in:
- International Journal of Molecular Sciences, 2022, v. 23, n. 24, p. 16170, doi. 10.3390/ijms232416170
- By:
- Publication type:
- Article
MAFb protein confers intrinsic resistance to proteasome inhibitors in multiple myeloma.
- Published in:
- 2018
- By:
- Publication type:
- journal article
Optimisation of anti-interleukin-6 therapy: Precision medicine through mathematical modelling.
- Published in:
- Frontiers in Immunology, 2022, v. 13, p. 1, doi. 10.3389/fimmu.2022.919489
- By:
- Publication type:
- Article
Human Placenta-Derived Adherent Cells Prevent Bone loss, Stimulate Bone formation, and Suppress Growth of Multiple Myeloma in Bone.
- Published in:
- Stem Cells, 2011, v. 29, n. 2, p. 263, doi. 10.1002/stem.572
- By:
- Publication type:
- Article
The disease course of Castleman disease patients with fatal outcomes in the ACCELERATE registry.
- Published in:
- British Journal of Haematology, 2022, v. 198, n. 2, p. 307, doi. 10.1111/bjh.18214
- By:
- Publication type:
- Article
High‐risk transcriptional profiles in multiple myeloma are an acquired feature that can occur in any subtype and more frequently with each subsequent relapse.
- Published in:
- British Journal of Haematology, 2021, v. 195, n. 2, p. 283, doi. 10.1111/bjh.17670
- By:
- Publication type:
- Article
Infectious and immunological sequelae of daratumumab in multiple myeloma.
- Published in:
- British Journal of Haematology, 2019, v. 185, n. 1, p. 187, doi. 10.1111/bjh.15433
- By:
- Publication type:
- Article
Second primary malignancies after tandem autologous hematopoietic stem cell transplantation for multiple myeloma.
- Published in:
- American Journal of Hematology, 2024, v. 99, n. 11, p. 2222, doi. 10.1002/ajh.27452
- By:
- Publication type:
- Article
Development and validation of an individualized and weighted Myeloma Prognostic Score System (MPSS) in patients with newly diagnosed multiple myeloma.
- Published in:
- American Journal of Hematology, 2024, v. 99, n. 4, p. 523, doi. 10.1002/ajh.27207
- By:
- Publication type:
- Article
Siltuximab administration results in spurious IL‐6 elevation in peripheral blood.
- Published in:
- American Journal of Hematology, 2024, v. 99, n. 1, p. E15, doi. 10.1002/ajh.27132
- By:
- Publication type:
- Article
Ongoing symptoms following complete surgical excision in unicentric Castleman disease.
- Published in:
- American Journal of Hematology, 2023, v. 98, n. 11, p. E334, doi. 10.1002/ajh.27065
- By:
- Publication type:
- Article
First‐ versus second‐generation Bruton tyrosine kinase inhibitors in Waldenström's Macroglobulinemia: A systematic review and meta‐analysis.
- Published in:
- American Journal of Hematology, 2022, v. 97, n. 7, p. 942, doi. 10.1002/ajh.26552
- By:
- Publication type:
- Article
Tandem autologous stem cell transplantation in patients with persistent bone marrow minimal residual disease after first transplantation in multiple myeloma.
- Published in:
- American Journal of Hematology, 2022, v. 97, n. 6, p. E195, doi. 10.1002/ajh.26530
- By:
- Publication type:
- Article
Validated international definition of the thrombocytopenia, anasarca, fever, reticulin fibrosis, renal insufficiency, and organomegaly clinical subtype (TAFRO) of idiopathic multicentric Castleman disease.
- Published in:
- American Journal of Hematology, 2021, v. 96, n. 10, p. 1241, doi. 10.1002/ajh.26292
- By:
- Publication type:
- Article
Persistent bone marrow minimal residual disease as a "high‐risk" disease feature in multiple myeloma.
- Published in:
- American Journal of Hematology, 2021, v. 96, n. 9, p. E341, doi. 10.1002/ajh.26255
- By:
- Publication type:
- Article
Bispecific BCMA/CD24 CAR-T cells control multiple myeloma growth.
- Published in:
- Nature Communications, 2024, v. 15, n. 1, p. 1, doi. 10.1038/s41467-024-44873-4
- By:
- Publication type:
- Article
Expression of integrin β-7 is epigenetically enhanced in multiple myeloma subgroups with high-risk cytogenetics.
- Published in:
- Clinical Epigenetics, 2023, v. 15, n. 1, p. 1, doi. 10.1186/s13148-023-01433-9
- By:
- Publication type:
- Article
Characterization of the Molecular Mechanism of the Bone-Anabolic Activity of Carfilzomib in Multiple Myeloma.
- Published in:
- PLoS ONE, 2013, v. 8, n. 9, p. 1, doi. 10.1371/journal.pone.0074191
- By:
- Publication type:
- Article
Interleukin-6 Receptor Polymorphism Is Prevalent in HIV-negative Castleman Disease and Is Associated with Increased Soluble Interleukin-6 Receptor Levels.
- Published in:
- PLoS ONE, 2013, v. 8, n. 1, p. 1, doi. 10.1371/journal.pone.0054610
- By:
- Publication type:
- Article
Myeloid transformation of plasma cell myeloma: molecular evidence of clonal evolution revealed by next generation sequencing.
- Published in:
- Diagnostic Pathology, 2018, v. 13, p. 1, doi. 10.1186/s13000-018-0692-1
- By:
- Publication type:
- Article
Geographic and Racial Disparities in Access to Chimeric Antigen Receptor–T Cells and Bispecific Antibodies Trials for Multiple Myeloma.
- Published in:
- JAMA Network Open, 2022, v. 5, n. 8, p. e2228877, doi. 10.1001/jamanetworkopen.2022.28877
- By:
- Publication type:
- Article
Enrollment of Black Participants in Pivotal Clinical Trials Supporting US Food and Drug Administration Approval of Chimeric Antigen Receptor–T Cell Therapy for Hematological Malignant Neoplasms.
- Published in:
- JAMA Network Open, 2022, v. 5, n. 4, p. e228161, doi. 10.1001/jamanetworkopen.2022.8161
- By:
- Publication type:
- Article
3195 Genomic Analysis of Primary Plasma Cell Leukemia reveals Complex Cytogenetic Alterations and High Risk Mutational Patterns.
- Published in:
- 2019
- By:
- Publication type:
- Abstract
A Risk Stratification System in Myeloma Patients with Autologous Stem Cell Transplantation.
- Published in:
- Cancers, 2024, v. 16, n. 6, p. 1116, doi. 10.3390/cancers16061116
- By:
- Publication type:
- Article
EDNRA-Expressing Mesenchymal Cells Are Expanded in Myeloma Interstitial Bone Marrow and Associated with Disease Progression.
- Published in:
- Cancers, 2023, v. 15, n. 18, p. 4519, doi. 10.3390/cancers15184519
- By:
- Publication type:
- Article
Epigenetic Deregulation of Telomere-Related Genes in Newly Diagnosed Multiple Myeloma Patients.
- Published in:
- Cancers, 2021, v. 13, n. 24, p. 6348, doi. 10.3390/cancers13246348
- By:
- Publication type:
- Article
Salvage Autologous Stem Cell Transplantation in Daratumumab-Refractory Multiple Myeloma.
- Published in:
- Cancers, 2021, v. 13, n. 16, p. 4019, doi. 10.3390/cancers13164019
- By:
- Publication type:
- Article
Impact of prior lenalidomide or proteasome inhibitor exposure on the effectiveness of ixazomib–lenalidomide–dexamethasone for relapsed/refractory multiple myeloma: A pooled analysis from the INSURE study.
- Published in:
- European Journal of Haematology, 2024, v. 113, n. 2, p. 190, doi. 10.1111/ejh.14214
- By:
- Publication type:
- Article
Combinatorial treatment for unresectable unicentric Castleman disease.
- Published in:
- European Journal of Haematology, 2021, v. 107, n. 4, p. 484, doi. 10.1111/ejh.13685
- By:
- Publication type:
- Article
Monitoring treatment response and disease progression in myeloma with circulating cell‐free DNA.
- Published in:
- European Journal of Haematology, 2021, v. 106, n. 2, p. 230, doi. 10.1111/ejh.13541
- By:
- Publication type:
- Article
Superior 12-Year Survival After at Least 4-Year Continuous Remission with Tandem Transplantations for Multiple Myeloma.
- Published in:
- Clinical Lymphoma & Myeloma, 2006, v. 6, n. 6, p. 469
- By:
- Publication type:
- Article
Idiopathic multicentric Castleman disease treated with siltuximab for 15 years: a case report.
- Published in:
- Therapeutic Advances in Hematology, 2022, v. 13, p. 1, doi. 10.1177/20406207221082552
- By:
- Publication type:
- Article
Patterns of central nervous system involvement in relapsed and refractory multiple myeloma.
- Published in:
- 2014
- By:
- Publication type:
- Journal Article
Completion of Premaintenance Phases in Total Therapies 2 and 3 Improves Clinical Outcomes in Multiple Myeloma.
- Published in:
- Cancer (0008543X), 2008, v. 112, n. 12, p. 2720, doi. 10.1002/cncr.23487
- By:
- Publication type:
- Article
High-dose melphalan-based autotransplants for multiple myeloma: the Arkansas experience since 1989 in 3077 patients.
- Published in:
- 2008
- By:
- Publication type:
- journal article
TRIP13 modulates protein deubiquitination and accelerates tumor development and progression of B cell malignancies.
- Published in:
- 2021
- By:
- Publication type:
- journal article
Fulminant onset of acute leukemia from normal hematopoiesis within 3 months of follow up for multiple myeloma treated with total therapy protocols.
- Published in:
- Clinical Case Reports, 2015, v. 3, n. 3, p. 183, doi. 10.1002/ccr3.180
- By:
- Publication type:
- Article
Profile of elotuzumab and its potential in the treatment of multiple myeloma.
- Published in:
- Blood & Lymphatic Cancer: Targets & Therapy, 2014, v. 4, p. 15, doi. 10.2147/BLCTT.S49780
- By:
- Publication type:
- Article
Rates of Influenza and Pneumococcal Vaccination and Correlation With Survival in Multiple Myeloma Patients.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2023, v. 23, n. 3, p. e171, doi. 10.1016/j.clml.2022.12.003
- By:
- Publication type:
- Article
Circulating cell free DNA is a biomarker for GEP70 risk score and tumor burden in myeloma.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2019, v. 19, p. e62, doi. 10.1016/j.clml.2019.09.096
- By:
- Publication type:
- Article
Long-term Analysis Of Multiple Sequential Samples Reveals Patterns Of Progression In Smoldering Myeloma.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2019, v. 19, p. e59, doi. 10.1016/j.clml.2019.09.092
- By:
- Publication type:
- Article
A tale of two paradigms: fixed duration vs continuous therapy in routine clinical practice: An INSIGHT MM study analysis of duration of therapy.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2019, v. 19, p. e4, doi. 10.1016/j.clml.2019.09.006
- By:
- Publication type:
- Article
Atrial Fibrillation in Hematologic Malignancies, Especially After Autologous Hematopoietic Stem Cell Transplantation: Review of Risk Factors, Current Management, and Future Directions.
- Published in:
- 2016
- By:
- Publication type:
- journal article